Nevro Stock Forecast, Price & News

Nevro's stock was trading at $109.82 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NVRO shares have increased by 42.6% and is now trading at $156.59.
View which stocks have been most impacted by COVID-19.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 3 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Nevro or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Nevro a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Nevro wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Nevro is scheduled to release its next quarterly earnings announcement on Tuesday, February 23rd 2021.
View our earnings forecast for Nevro.

Nevro Corp. (NYSE:NVRO) released its quarterly earnings data on Thursday, November, 5th. The medical equipment provider reported ($0.29) EPS for the quarter, beating the Zacks' consensus estimate of ($0.59) by $0.30. The medical equipment provider had revenue of $108.46 million for the quarter, compared to analyst estimates of $104 million. Nevro had a negative net margin of 27.22% and a negative return on equity of 38.86%. The firm's revenue for the quarter was up 8.3% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.58) earnings per share.
View Nevro's earnings history.

13 Wall Street analysts have issued 12 month price targets for Nevro's stock. Their forecasts range from $100.00 to $190.00. On average, they expect Nevro's stock price to reach $155.36 in the next twelve months. This suggests that the stock has a possible downside of 0.8%.
View analysts' price targets for Nevro.

Some companies that are related to Nevro include Teleflex (TFX), Insulet (PODD), NovoCure (NVCR), Abiomed (ABMD), Penumbra (PEN), Hill-Rom (HRC), Globus Medical (GMED), Tandem Diabetes Care (TNDM), Haemonetics (HAE), iRhythm Technologies (IRTC), Inspire Medical Systems (INSP), Integra LifeSciences (IART), ICU Medical (ICUI), Glaukos (GKOS) and Inari Medical (NARI).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), The Walt Disney (DIS), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Adobe (ADBE) and Intuitive Surgical (ISRG).

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Nevro's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (10.15%), Jackson Square Partners LLC (2.99%), Lord Abbett & CO. LLC (2.16%), State Street Corp (2.09%), Victory Capital Management Inc. (1.27%) and Jennison Associates LLC (1.08%). Company insiders that own Nevro stock include Andrew H Galligan, Doug Alleavitch, Elizabeth H Weatherman, Kevin C Oboyle, Michael F Demane, Niamh Louise Pellegrini and Shawn Mccormick.
View institutional ownership trends for Nevro.

NVRO stock was sold by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, Tiger Eye Capital LLC, Jackson Square Partners LLC, State Street Corp, Sei Investments Co., Robeco Institutional Asset Management B.V., First Trust Advisors LP, and Thrivent Financial for Lutherans. Company insiders that have sold Nevro company stock in the last year include Andrew H Galligan, Michael F Demane, Niamh Louise Pellegrini, and Shawn Mccormick.
View insider buying and selling activity for Nevro.

NVRO stock was bought by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Point72 Asset Management L.P., Lord Abbett & CO. LLC, Summit Partners Public Asset Management LLC, Granite Investment Partners LLC, Victory Capital Management Inc., Squarepoint Ops LLC, and BlackRock Inc.. Company insiders that have bought Nevro stock in the last two years include Elizabeth H Weatherman, and Kevin C Oboyle.
View insider buying and selling activity for Nevro.

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVRO stock can currently be purchased for approximately $156.59.

Nevro has a market capitalization of $5.39 billion and generates $390.26 million in revenue each year. The medical equipment provider earns $-103,690,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. Nevro employs 853 workers across the globe.

The official website for Nevro is www.nevro.com.

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]